A Prospective Cohort Study of China Serum Uric Acid Levels

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3535 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-11-20

Study Completion Date

2018-06-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Uric acid is the final breakdown product of purine degradation in humans. The association between high serum uric acid levels and arterial stiffness as well as endothelial dysfunction has been demonstrated in humans and uric acid has been suggested to be an important modulator of the inflammatory process. But debates still existed for hyperuricemia and hypouricemia as an independent role,especially after controlling other traditional atherosclerotic risk.The aim of this study was, firstly, to verify the association between hyperuricemia and cardiovascular diseases,secondly,to assess whether hypouricemia was an independent risk factor impact for cardiovascular disea.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ankle Brachial Index Combined With Serum Uric Acid Levels Improve Prediction All Cause Mortality and Cardiovascular Mortality in the Elderly Chinese Population

NCT03616418

Ankle Brachial Index

COMPLETED

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

NCT03185793

Hyperuricemia

COMPLETED PHASE2

Uric Acid Study in Healthy Male Volunteers

NCT00738842

Gout Coronary Artery Disease

COMPLETED PHASE1

Association Between Uric Acid and Acute Coronary Syndrome

NCT05770323

Acute Coronary Syndrome

UNKNOWN

Multiple Dose Study of SHR4640 in Healthy Subjects

NCT02890966

Gout; Hyperuricemia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a longitudinal cohort study. The first cross-sectional survey was conducted in 2011. The eligible participants were followed up from November 2011 to June 2018 (mean follow-up months 68.71±11.35). During the followed-up time, 67 patients had missing data and 56 had no compliance. Thus, the study sample actually comprised 3,047 valid participants (1536 men, 1511 women) whose age older than or equal to 35 years (mean age 60.2±10.4 years) were followed up. A total of hospitalized patients were consecutively enrolled from cardiology department of Beijing and Shanghai. All subjects are under treatment because of cardiovascular diseases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uric Acid Serum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

quantiles of serum uric acid level

quantiles according to the patient's serum uric acid level

antiplatelet drugs ,statins ,antihypertensive drugs

Intervention Type DRUG

According to the international guidelines, we treated patients who suffered from different disease.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

antiplatelet drugs ,statins ,antihypertensive drugs

According to the international guidelines, we treated patients who suffered from different disease.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

age older than or equal to 35 years with multiple classical Framingham risk factors patients.

Exclusion Criteria

Severe congestive heart failure and Severe renal failure patients.Severe congestive heart failure was defined that above or equal to cardiac functional classify 3 formulated by New York Heart Association (NYHA). Severe renal failure was defined as an estimated glomerular filtration rate \<60 ml/ min/1.73m2.

Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No